Moderna withdraws application for COVID-flu combination vaccine

Moderna has withdrawn its application for FDA approval of its combination COVID-19 and flu vaccine for adults 50 and older, citing the need to include efficacy data from a late-stage trial of its seasonal influenza vaccine; the company plans to resubmit the application later this year, pending interim data expected this summer. This decision follows the FDA's announcement that new clinical trials will be required for annual COVID-19 boosters for healthy individuals under 65, potentially impacting Moderna's future vaccine strategy.

Analysis

Moderna (MRNA.O) has announced the withdrawal of its regulatory application for its combination COVID-19 and influenza vaccine candidate targeted at adults aged 50 and older. This strategic decision is driven by the company's intent to incorporate forthcoming efficacy data from a late-stage trial of its standalone experimental seasonal influenza vaccine, with interim results anticipated this summer, leading Moderna to plan a resubmission of the combined vaccine application later in the year. This development occurs concurrently with a recent U.S. Food and Drug Administration (FDA) announcement that it will require new clinical trials for the approval of annual COVID-19 boosters for healthy individuals under 65. While the withdrawal introduces a delay to the market entry timeline for this specific combination product, the planned resubmission with additional data aims to bolster its approval prospects. The FDA's updated stance on booster trials may also carry broader implications for Moderna's future clinical development and regulatory strategies concerning its COVID-19 vaccine franchise. The market sentiment specific to MRNA reflects a slightly negative reaction to this news, as indicated by a sentiment score of -0.3, although the overall market impact is perceived as low.

Key Decisions for Investors

• Investors should monitor the interim efficacy data from Moderna's seasonal influenza vaccine trial expected this summer, as this will be crucial for the resubmission timeline and outlook for the combination vaccine.
• Factor in a potential delay in revenue generation from the COVID-flu combination vaccine due to the current withdrawal and planned resubmission later this year.
• Closely track evolving FDA guidance on COVID-19 booster trial requirements, particularly for healthy individuals under 65, as this presents a regulatory variable that could affect Moderna's future vaccine strategy and market access.